CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 45 enrolled
Drug / intervention
Tirzepatidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03482024
NCT03482024Phase 1Completed
CompareCT.gov

Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function

Eli Lilly and Company·interventional·Posted Mar 29, 2018·Updated Mar 23, 2023

In Brief

A Phase 1 clinical trial evaluating Tirzepatide for Renal Insufficiency and End Stage Renal Disease. Completed, enrolled 45 participants across 4 sites.

Detailed Summary

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Insufficiency, End Stage Renal Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartMar 30, 2018
Primary CompletionAug 19, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.3 years ago

Interventions

Tirzepatidedrug

Administered SC.